2024
The combination of CDX2 expression status and tumor-infiltrating lymphocyte density as a prognostic factor in adjuvant FOLFOX-treated patients with stage III colorectal cancers
Lee J, Park H, Jin H, Jin L, Yoo S, Cho N, Bae J, Kim J, Kang G. The combination of CDX2 expression status and tumor-infiltrating lymphocyte density as a prognostic factor in adjuvant FOLFOX-treated patients with stage III colorectal cancers. Journal Of Pathology And Translational Medicine 2024, 59: 50-59. PMID: 39440351, PMCID: PMC11736276, DOI: 10.4132/jptm.2024.09.26.Peer-Reviewed Original ResearchTumor-infiltrating lymphocytesCaudal-type homeobox 2CD8 tumor-infiltrating lymphocytesTumor-infiltrating lymphocyte densitySurvival of patientsColorectal carcinomaStromal areaClinical outcomesHigh density of tumor-infiltrating lymphocytesDensity of tumor-infiltrating lymphocytesAdjuvant chemotherapy-treated patientsStage III colorectal carcinomaStage III colorectal cancerFOLFOX-treated patientsCancer-specific survivalChemotherapy-treated patientsIII colorectal carcinomaIII colorectal cancerTIL densityPrognostic factorsPrognostic parametersLymphocyte densityPrognostic markerCDX2 expressionColorectal cancer
2021
Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition
Litchfield K, Reading J, Puttick C, Thakkar K, Abbosh C, Bentham R, Watkins T, Rosenthal R, Biswas D, Rowan A, Lim E, Al Bakir M, Turati V, Guerra-Assunção J, Conde L, Furness A, Saini S, Hadrup S, Herrero J, Lee S, Van Loo P, Enver T, Larkin J, Hellmann M, Turajlic S, Quezada S, McGranahan N, Swanton C. Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition. Cell 2021, 184: 596-614.e14. PMID: 33508232, PMCID: PMC7933824, DOI: 10.1016/j.cell.2021.01.002.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorCD8 AntigensChemokine CXCL13Chromosomes, Human, Pair 9Cohort StudiesCyclin D1DNA Copy Number VariationsExomeGene AmplificationHumansImmune Checkpoint InhibitorsImmune EvasionMultivariate AnalysisMutationNeoplasmsPolymorphism, Single NucleotideReceptors, CCR5T-LymphocytesTumor BurdenConceptsTumor mutational burdenTumor-infiltrating lymphocytesHistocompatibility leukocyte antigenCheckpoint inhibitorsCD8 tumor-infiltrating lymphocytesCPI-treated patientsTumor cell-intrinsicClinical outcome criteriaCopy-number analysisCXCL9 expressionCCND1 amplificationMutational burdenLeukocyte antigenTumor typesMultivariate predictorsSingle-cell RNA sequencingAdaptive immunityAssociated with resistanceWhole exomeMicroenvironmental featuresOutcome criteriaCopy-numberFunctional evidenceRNA-seqTumor
2019
Abstract 2700: CD8 T-cell infiltration into renal tumors requires a supportive antigen-presenting niche
Jansen C, Prokhnevska N, Master V, Carlisle J, Bilen M, Reyes A, Kissick H. Abstract 2700: CD8 T-cell infiltration into renal tumors requires a supportive antigen-presenting niche. Cancer Research 2019, 79: 2700-2700. DOI: 10.1158/1538-7445.am2019-2700.Peer-Reviewed Original ResearchCD8 T cell infiltrationT cell infiltrationTumor-infiltrating lymphocytesT cell responsesRenal cell carcinomaStem-like T cellsCancer-specific survivalT cellsRenal tumorsPatient survivalCD8 tumor-infiltrating lymphocytesPoor T-cell infiltrationDisease progressionAnti-tumor immune responseCD8 T cell responsesImmune responseTumor-infiltrating immune cellsFlow cytometryRenal cell carcinoma patientsCD8 T cellsStage III patientsIntensification of therapyRenal cell tumorsFollow-up timeEmory University Hospital
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply